scholarly journals The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

2013 ◽  
Vol 51 (11) ◽  
pp. 3653-3657 ◽  
Author(s):  
D. A. M. Heideman ◽  
A. T. Hesselink ◽  
F. J. van Kemenade ◽  
T. Iftner ◽  
J. Berkhof ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Screening ◽  
Cross Sectional ◽  
International Guidelines ◽  
The Cross ◽  
Test Requirements

scholarly journals Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

2020 ◽  
Author(s):  
Ditte Møller Ejegod ◽  
Camilla Lagheden ◽  
Ramya Bhatia ◽  
Helle Pedersen ◽  
Elia Alcañiz Boada ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Cervical Screening ◽  
Screening Methods ◽  
International Guidelines ◽  
Screening Programs ◽  
Test Requirements

Abstract Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening. Methods The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1,184 SurePath and 1,169 ThinPrep samples from women with

scholarly journals Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study

2008 ◽  
Vol 99 (11) ◽  
pp. 1929-1933 ◽  
Author(s):  
S Hibbitts ◽  
J Jones ◽  
N Powell ◽  
N Dallimore ◽  
J McRea ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Screening ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
South Wales

scholarly journals Cervical Cancer and Human Papillomavirus Awareness among Women in Saudi Arabia

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1373
Author(s):  
Khalid Akkour ◽  
Lolowah Alghuson ◽  
Hicham Benabdelkamel ◽  
Hani Alhalal ◽  
Nada Alayed ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Saudi Arabia ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Public Awareness ◽  
Cervical Screening ◽  
The Internet ◽  
Cross Sectional ◽  
Saudi Women ◽  
Source Of Information

Background and Objectives: Cervical cancer (CC) is the eighth most common cancer among Saudi women of all ages. With limited national data, we aimed to evaluate the public awareness of cervical cancer, CC risk factors, HPV infection, and HPV vaccines in different regions of Saudi Arabia. Materials and Methods: This was a survey-based cross-sectional study that encompassed 564 Saudi women over a period of a month. A self-administrated questionnaire was distributed through different social media platforms. Results: The collected data included sociodemographic variables and questions assessing awareness of CC, and the attitudes toward CC screening and human papillomavirus (HPV) vaccination. Most respondents were aware of CC (84.0%), although their primary source of information was the internet. However, only 45 females (8.0%) had a history of cervical screening. Furthermore, most females did not know that HPV was transmitted sexually (78.9%), or that it caused genital warts (81.7%) and CC (81.9%). Regarding the HPV vaccine, 100 females (17.7%) had heard about it, but only 11 (2.0%) took the vaccine, although more than half of the respondents (54.1%) were willing to take the vaccine after being informed about it. Conclusions: We noticed a remarkable lack of awareness among the respondents regarding HPV’s clinical implications; and the HPV vaccine, and its importance and availability. The main source of information for most of the Saudi women in this study was the internet, which may be an unreliable source, or provide misleading information that may delay screening or discourage vaccination. Thus, organized campaigns by the Ministry of Health or other health-advocating agencies, in addition to screening and vaccination programs, are strongly encouraged.

scholarly journals The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

2016 ◽  
Vol 54 (9) ◽  
pp. 2267-2272 ◽  
Author(s):  
Ditte Ejegod ◽  
Fabio Bottari ◽  
Helle Pedersen ◽  
Maria Teresa Sandri ◽  
Jesper Bonde
Keyword(s):  
Cervical Cancer ◽  
Cervical Screening ◽  
Clinical Validation ◽  
Confidence Bound ◽  
International Guidelines ◽  
Lower Confidence ◽  
Hpv Test ◽  
Lower Confidence Bound ◽  
Kappa Value ◽  
Test Requirements

This study describes a validation of the BD Onclarity HPV (Onclarity) assay using the international guidelines for HPV test requirements for cervical cancer screening of women 30 years old and older using Danish SurePath screening samples. The clinical specificity (0.90, 95% confidence interval [CI] = 0.88 to 0.91) and sensitivity (0.97, 95% CI = 0.87 to 1.0) of the Onclarity assay were shown to be not inferior to the reference assay (specificity, 0.90 [95% CI = 0.88 to 0.92]; sensitivity, 0.98 [95% CI = 0.91 to 1.0]). The intralaboratory reproducibility of Onclarity was 97%, with a lower confidence bound of 96% (kappa value, 0.93). The interlaboratory agreement was 97%, with a lower confidence bound of 95% (kappa value, 0.92). The BD Onclarity HPV assay fulfills all the international guidelines for a new HPV test to be used in primarily screening. This is the first clinical validation of a new HPV assay using SurePath screening samples, and thus the Onclarity HPV assay is the first HPV assay to hold an international validation for both SurePath and ThinPrep.

scholarly journals Genotype Distribution Change After Human Papillomavirus Vaccination in Two Autonomous Communities in Spain

2021 ◽  
Vol 11 ◽  
Author(s):  
Javier Freire-Salinas ◽  
Rafael Benito ◽  
Ainara Azueta ◽  
Joaquina Gil ◽  
Claudia Mendoza ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Screening ◽  
Hpv Vaccination ◽  
Uterine Cervical Cancer ◽  
Vaccination Program ◽  
Genotype Distribution ◽  
Human Papillomavirus Vaccination ◽  
Cross Sectional ◽  
Autonomous Communities ◽  
Hpv Dna

ContextIt has been more than 10 years since the human papillomavirus (HPV) vaccination program was initiated in most advanced countries. Thus, it seems necessary to change the uterine cervical cancer screening strategy. Molecular-based tests are considered essential in this scenario.ObjectiveWe aimed to review the distribution of the HPV genotypes after the introduction of the vaccination program with Cervarix® and Gardasil 4® in two autonomous communities in Spain, looking for possible changes in distribution and the occurrence of a herd effect.DesignA cross-sectional study was performed in 45,362 samples that were processed in the Cantabria and Aragon communities during the period from 2002 to 2016. We compared the genotype distribution before and after the vaccination program was initiated.ResultsGenotypes HPV6 and HPV11 have decreased significantly after the introduction of the vaccine. HPV16 has had a decrease, but not a significant one in the statistical analysis. However, HPV31, HPV52, and HPV45 have increased in percentage. A replacement phenomenon with other genotypes not included in the vaccine has been observed in our population.ConclusionsContinued surveillance is needed to provide further indication of any changes over time in the genotypes in circulation. This will be facilitated by monitoring the genotyping results from the new model of cervical screening using primary HPV DNA testing.

Sign in / Sign up

Export Citation Format

Share Document